1. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. (28th October 2021) Authors: Dougan, Michael; Azizad, Masoud; Mocherla, Bharat; Gottlieb, Robert L; Chen, Peter; Hebert, Corey; Perry, Russell; Boscia, Joseph; Heller, Barry; Morris, Jason; Crystal, Chad; Igbinadolor, Awawu; Huhn, Gregory; Cardona, Jose; Shawa, Imad; Kumar, Princy; Blomkalns, Andra; Adams, Andrew C; Van Naar... Journal: Clinical infectious diseases Issue: Volume 75:Number 1(2022) Page Start: e440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Issue 10 (October 2021) Authors: Valle, Juan W; Vogel, Arndt; Denlinger, Crystal S; He, Aiwu Ruth; Bai, Li-Yuan; Orlova, Rashida; Van Cutsem, Eric; Adeva, Jorge; Chen, Li-Tzong; Obermannova, Radka; Ettrich, Thomas J; Chen, Jen-Shi; Wasan, Harpreet; Girvan, Allicia C; Zhang, Wei; Liu, Jiangang; Tang, Chunlao; Ebert, Philip J; Agg... Journal: Lancet oncology Issue: Volume 22:Issue 10(2021) Page Start: 1468 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗